Boiron SA BOIRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $36.46
- Day Range
- $36.81–36.81
- 52-Week Range
- $35.25–53.50
- Bid/Ask
- $33.91 / $39.34
- Market Cap
- $639.63 Mil
- Volume/Avg
- 100 / 169
Key Statistics
- Price/Earnings (Normalized)
- 12.45
- Price/Sales
- 1.20
- Dividend Yield (Trailing)
- 3.22%
- Dividend Yield (Forward)
- 4.18%
- Total Yield
- 3.24%
Company Profile
Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,810
- Website
- http://www.boiron.com
Comparables
Valuation
|
Metric
|
BOIRF
|
VETO
|
HROW
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.45 | 14.18 | — |
Price/Book Value | 1.47 | 2.34 | 5.23 |
Price/Sales | 1.20 | 2.25 | 2.64 |
Price/Cash Flow | 14.78 | 12.46 | 31.29 |
Price/Earnings
BOIRF
VETO
HROW
Financial Strength
|
Metric
|
BOIRF
|
VETO
|
HROW
|
|---|---|---|---|
Quick Ratio | 1.31 | 1.65 | 2.42 |
Current Ratio | 2.27 | 2.68 | 2.83 |
Interest Coverage | 34.07 | 71.00 | −0.11 |
Quick Ratio
BOIRF
VETO
HROW
Profitability
|
Metric
|
BOIRF
|
VETO
|
HROW
|
|---|---|---|---|
Return on Assets (Normalized) | 5.80% | 8.74% | −3.03% |
Return on Equity (Normalized) | 8.17% | 11.48% | −16.62% |
Return on Invested Capital (Normalized) | 7.38% | 10.78% | 4.51% |
Return on Assets
BOIRF
VETO
HROW
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Wfrdjznqp | Hccbj | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Dndxsvnms | Fwdvh | $70.8 Bil | |
HLN
| Haleon PLC ADR | Hrwbxnww | Jyfz | $37.7 Bil | |
VTRS
| Viatris Inc | Qtkllkl | Jbbdp | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ygjqcrp | Gcl | $12.5 Bil | |
CTLT
| Catalent Inc | Mkqpdyn | Xmjbcfj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Mxkcxsh | Rjvy | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Tlcfwvsl | Qhbfj | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ccdsxdx | Wbtfcx | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Dbmrxtspw | Tbxnz | $2.9 Bil |